Tag: KEYTRUDA

April 8, 2019

Neon Therapeutics Completes Enrollment in Phase 1b NT-002 Clinical Trial for Metastatic Non-Small Cell Lung Cancer

Neon Therapeutics (NASDAQ:NTGN) has announced it has completed enrollment of NT-002, its Phase 1b clinical trial evaluating NEO-PV-01 with KEYTRUDA...
February 28, 2019

Innovation in Breast Cancer Treatment: Combination and Off-the-Shelf Personalized Immunotherapies

Advancements for breast cancer patients are being led by breast cancer combination therapy innovations, and off-the-shelf personalized immunotherapy
January 3, 2019

Big Pharma Collaboration Announced with Cocystal and Merck

Cocrystal Pharma and Merck have announced a new partnership that ignited investor attention in early trading on Thursday.
December 6, 2018

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference

BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces the presentation of...
November 13, 2018

CRISPR Trials to Watch in 2018

CRISPR Cas-9 gene editing is finally in clinical studies. Here's an overview of CRISPR genetics testing trials currently in progress.
October 14, 2018

10 Drugs Going Off Patent in 2018

A look at 10 drugs going off patent in 2018, plus an overview of what loss of exclusivity means for...
September 20, 2018

Galectin Therapeutics Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA

Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced additional preliminary clinical data from...